Cardiovascular Drugs Market Estimated to Flourish by 2025


According to the research report, The Global Cardiovascular Drugs Market was valued at US$ 142.56 bn in 2016. Between the forecast period of 2017 and 2025, the global market is expected to register a CAGR of 1.5% to reach a valuation of US$162.96 bn by the end of 2025.The World Health Organization stated that about 31% of the deaths across the world in 2015 were due to cardiovascular diseases (CVD). Analysts anticipate that CVD related to the heart and blood are expected to remain on the rise in the coming years. Changing lifestyles, poor dietary intake, and genetic predisposition are expected to increase the demand for cardiovascular drugs in the near future. Poor lifestyle choices such as excessive drinking, smoking, and eating junk food have deteriorated heart health of a vast population base across the globe. Furthermore, conditions such as diabetes, high cholesterol, depression, and obesity have also played a significant role in spiking the demand for cardiovascular drugs all over the world.

Geographically, the global cardiovascular drugs market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to dominate the global market owing to high prevalence of cardiovascular diseases, high per capita healthcare expenditure and comparatively higher cost of cardiovascular drugs in the region. Europe is projected to account for prominent share of global cardiovascular drugs market during the forecast period owing to well established health care infrastructure and increasing incidences of cardiovascular diseases. Asia Pacific with its considerably established market such as Japan and emerging markets such as India and China is projected to witness an exponential growth during the forecast period.

Leading players such as AstraZeneca, Pfizer, and Novartis are expected to make bold moves during the forecast period of 2017 and 2025. Increasing investments in research and development and growing number of medical trials are expected to have to intensify the competition in the global market. Mergers and acquisitions are also anticipated to be a key strategy of the players to show their dominance in the global market. For instance, AstraZeneca and Recordati have agreed to work together to gain commercial rights to retail Seloken along with related Logimax fixed-dose combination treatments all across Europe.

Report Overview, with TOC –

Leave a Reply